A relatively new actor in the biopharmaceutical industry, BTB Pharma is a developer of a revolutionary biomedical platform for the treatment of autoimmune disease.
With an antigen-specific approach, the platform technology targets the cause of disease, not just the symptoms. This technology incorporates a two-component concept, creating a synergistic effect between the first component, which binds unique cells in the immune system, with the second component, which is disease-specific.
This configuration allows the treatment to combat a number of different autoimmune diseases. Currently, BTB Pharma’s aspirations lie in the treatment of Multiple Sclerosis and Type 1 Diabetes. Specific treatments are currently in a Proof of Concept format, and are being tested in relevant animal models.
